Registered with SFDA (Saudi Arabia) for dapagliflozin propanediol. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Registered with SFDA (Saudi Arabia) for dapagliflozin propanediol. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 10 markets.
Registered with SFDA (Saudi Arabia) for dapagliflozin propanediol. Its 2019 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
Registered with SFDA (Saudi Arabia) for dapagliflozin propanediol. Its GMP is recognised in 10 markets.
Registered with SFDA (Saudi Arabia) for dapagliflozin propanediol. Its 2023 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Registered with SFDA (Saudi Arabia) for dapagliflozin propanediol. Its 2022 FDA inspection closed as VAI.
Registered with SFDA (Saudi Arabia) for dapagliflozin propanediol. Its GMP is recognised in 1 market.
Registered with SFDA (Saudi Arabia) for dapagliflozin propanediol.
Registered with SFDA (Saudi Arabia) for dapagliflozin propanediol. Its 2025 FDA inspection closed as OAI, and its GMP is recognised in 1 market.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for freeFixed-dose combinations containing dapagliflozin propanediol. Each page leads with the verified API makers of every component.